文献速递重症综合管理与镇静镇痛

建立信任与减轻代理知情同意过程中压力的方法:重症研究中的混合方法研究

Approaches for Establishing Trust and Alleviating Stress During the Surrogate Informed Consent Process for Critical Care Research.
PubMed 文献 · Chest · 2025-07-23
一句话结论重症研究代理知情同意中,将患者人性化、针对患者/代理决策者背景定制沟通、透明沟通研究细节是建立信任和减轻压力的三大策略。

该 convergent parallel 混合方法研究通过问卷调查、焦点小组和半结构化访谈,纳入主要研究者、研究协调员、代理决策者和重症患者,探讨在重症研究代理知情同意过程中建立信任和减轻压力的方法。共230人完成问卷(90名主要研究者、105名研究协调员、27名代理决策者、8名患者),61人参与焦点小组/访谈(24名主要研究者、23名研究协调员、11名代理决策者、3名患者)。研究识别出三种策略:将研究参与人性化、根据患者/代理决策者背景定制方法、透明沟通研究细节。参与者认为研究者首先需要将患者视为「人」而非研究参与者,花时间了解并处理患者或代理决策者的背景很重要。

要点

  • 重症研究代理知情同意中,研究者首先需要展示他们考虑的是患者作为「人」而非研究参与者。
  • 三种被参与者认为对建立信任和减轻压力重要的策略:将研究参与人性化、根据患者/代理决策者背景定制方法、透明沟通研究细节。
  • 根据患者/代理决策者背景定制方法包括考虑种族、地点、既往研究经历等因素。
  • 花时间了解和解决患者或代理决策者背景的各个方面很重要,研究细节的沟通方式也很重要。
  • 尽管所有参与者群体对这些因素的相关性基本一致,但组间存在一些差异。

适用人群与场景

  • 被邀请代表重症患者参与重症研究临床试验知情同意的代理决策者。
  • 参与重症研究知情同意过程的主要研究者、研究协调员、代理决策者和重症患者。

处置流程与药物剂量

  • 将研究参与人性化:研究者首先需要展示他们考虑的是患者作为「人」,而非研究参与者。
  • 根据患者/代理决策者背景定制方法:考虑种族、地点、既往研究经历等背景因素,花时间了解和解决患者或代理决策者背景的各个方面。
  • 透明沟通研究细节:注意研究细节的沟通方式。

研究设计与关键结果

  • 研究设计为 convergent parallel 混合方法研究,包括问卷调查、焦点小组和半结构化访谈。
  • 共230人完成问卷:90名主要研究者、105名研究协调员、27名代理决策者、8名患者。
  • 共61人参与焦点小组/访谈:24名主要研究者、23名研究协调员、11名代理决策者、3名患者。
  • 识别出三种参与者描述的对建立信任和减轻代理决策者压力有意义的策略:将研究参与人性化、根据患者/代理决策者背景定制方法、透明沟通研究细节。
  • 参与者认为研究者首先需要展示他们考虑的是患者作为「人」,而非研究参与者;花时间了解和解决患者或代理决策者背景的各个方面很重要,研究细节的沟通方式也很重要。
  • 尽管所有参与者群体对这些因素的相关性基本一致,但组间存在一些差异。

证据类型、等级与局限

  • 证据类型:混合方法研究(问卷调查、焦点小组、半结构化访谈)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,纳入这些方法可以增强重症研究中的信任和参与。
  • 原文未据此给出具体临床推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Trust with researchers is a consideration among surrogate decision makers (SDMs) who are approached to provide consent for research participation on behalf of critically ill patients. However, little is known about strategies that researchers can use to build trust with SDMs and alleviate stress when making these decisions.

RESEARCH QUESTION: What are the best approaches to building trust and alleviating stress that can be used in the surrogate informed consent process?

STUDY DESIGN AND METHODS: This convergent parallel mixed-methods study included surveys, focus groups, and semi-structured interviews with principal investigators (PIs), research coordinators (RCs), SDMs, and critically ill patients who were approached for participation in a critical care research clinical trial. Surveys captured opinions regarding trust and stress in the surrogate consent process, and qualitative findings described factors that influenced the trust and stress of the SDMs in this context.

RESULTS: Overall, 230 individuals (90 PIs, 105 RCs, 27 SDMs, and 8 patients) completed surveys, and 61 (24 PIs, 23 RCs, 11 SDMs, and 3 patients) participated in focus groups/interviews. Three approaches were identified that participants described across data sources as significant for establishing trust and reducing stress among SDMs: (1) humanizing research participation; (2) tailoring approaches to patient/SDM background (eg, race, location, prior research experience); and (3) transparent communication about study details. Participants felt that researchers first needed to show that they were considering the patient as "a person," not as a study participant. Taking time to learn about and address aspects of the patient's or SDM's background was important, as was the manner in which study details were communicated. Although all participant groups largely agreed about the relevance of these factors, some differences between groups were noted.

INTERPRETATION: Three strategies were identified that PIs, RCs, SDMs, and patients viewed as effective for building trust and alleviating stress in the surrogate informed consent process. Incorporating these approaches could enhance trust and participation in critical care research.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Tietbohl CK, Glaros C, Torres KA, et al. Approaches for Establishing Trust and Alleviating Stress During the Surrogate Informed Consent Process for Critical Care Research. Chest. 2025. PMID: 40712948. doi:10.1016/j.chest.2025.06.050

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。